Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA) Institutional Ownership

CUSIP: 140755109

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
CARA on Nasdaq
Shares outstanding
54,790,889
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Investment Quick Answers

What is CUSIP 140755109?
CUSIP 140755109 identifies CARA - Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.

Significant Owners of Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Vifor (International) Ltd 14% $2,458,686 7,396,770 Vifor (International) Ltd. 17 Dec 2024

Institutional Holders of Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q1 0 $0 -$7,158 0
2024 Q4 20,164 $7,158 -$3,973,383 $0.36 1
2024 Q3 13,514,237 $4,159,096 -$1,032,751 $0.31 65
2024 Q2 17,684,088 $4,561,540 -$4,042,593 $0.26 76
2024 Q1 23,514,485 $21,396,518 -$426,875 $0.91 96
2023 Q4 24,377,112 $18,109,185 -$5,083,037 $0.74 107
2023 Q3 27,123,062 $45,563,127 -$6,587,024 $1.68 121
2023 Q2 29,289,778 $82,888,748 -$18,896,002 $2.83 131
2023 Q1 33,889,306 $166,391,687 -$5,477,111 $4.91 161
2022 Q4 33,996,854 $365,121,945 -$4,541,381 $10.74 161
2022 Q3 34,612,850 $323,992,355 -$2,083,804 $9.36 152
2022 Q2 34,812,812 $317,864,785 +$23,430,633 $9.13 166
2022 Q1 31,735,791 $385,591,868 +$16,589,053 $12.15 177
2021 Q4 30,295,793 $368,853,803 +$3,325,166 $12.18 174
2021 Q3 29,597,983 $457,112,862 +$1,903,784 $15.45 161
2021 Q2 29,619,793 $422,555,895 -$29,484,537 $14.27 162
2021 Q1 29,844,915 $647,894,469 +$3,235,940 $21.71 156
2020 Q4 29,864,210 $451,866,505 -$10,514,992 $15.13 146
2020 Q3 30,605,125 $389,630,505 +$7,883,789 $12.72 152
2020 Q2 29,920,527 $511,617,407 +$22,432,806 $17.10 136
2020 Q1 32,217,643 $425,460,027 +$9,271,004 $13.21 130
2019 Q4 31,365,475 $505,318,090 +$4,578,062 $16.11 146
2019 Q3 30,528,396 $558,121,704 +$81,405,292 $18.28 140
2019 Q2 26,022,034 $559,418,629 +$84,321,964 $21.50 122
2019 Q1 22,307,202 $437,676,305 -$26,628,851 $19.62 130
2018 Q4 24,252,310 $315,074,723 -$3,522,463 $13.00 129
2018 Q3 23,452,027 $561,612,752 +$111,415,387 $23.95 141
2018 Q2 18,764,234 $359,338,384 +$24,241,175 $19.15 122
2018 Q1 17,934,850 $221,836,124 +$8,896,641 $12.38 116
2017 Q4 13,668,528 $167,392,966 -$24,154,898 $12.24 122
2017 Q3 15,548,215 $212,721,305 -$11,553,188 $13.69 116
2017 Q2 19,921,450 $306,627,408 +$37,073,627 $15.39 125
2017 Q1 17,021,870 $312,676,249 +$101,013,666 $18.39 109
2016 Q4 13,764,777 $127,888,593 +$13,025,567 $9.29 98
2016 Q3 11,609,560 $96,937,885 +$6,055,428 $8.35 78
2016 Q2 11,908,919 $57,274,967 -$25,677,121 $4.81 63
2016 Q1 16,228,642 $100,929,732 -$43,522,582 $6.22 91
2015 Q4 19,629,819 $330,876,371 +$18,693,953 $16.86 93
2015 Q3 18,553,564 $265,128,131 +$93,669,119 $14.29 88
2015 Q2 12,065,581 $146,597,682 +$14,135,862 $12.15 74
2015 Q1 11,149,349 $112,187,948 +$13,425,176 $10.05 59
2014 Q4 9,218,398 $92,056,301 -$3,867,664 $9.97 54
2014 Q3 9,715,313 $81,499,006 +$5,569,556 $8.39 53
2014 Q2 8,774,155 $149,338,478 +$751,547 $17.02 47
2014 Q1 8,621,122 $160,437,942 +$160,207,942 $18.61 42